AAP
ARCT icon

Arax Advisory Partners’s Arcturus Therapeutics ARCT Stock Holding History

Arax Advisory Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$479 Buy
+62
New +$452 ﹤0.01% 3417
2025
Q4 		– Sell
-301
Closed -$5.55K – 4097
2025
Q3 		$5.55K Buy
301
+210
+231% +$3.37K ﹤0.01% 2839
2025
Q2 		$1.18K Buy
+91
New +$1.08K ﹤0.01% 2724
2024
Q4 		– Sell
-443
Closed -$10.3K – 2449
2024
Q3 		$10.3K Hold
443
– – ﹤0.01% 1402
2024
Q2 		$10.8K Buy
+443
New +$13.4K ﹤0.01% 1233

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's ARCT Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Arcturus Therapeutics (ARCT) in Q1 2026: 62 shares worth $479. The stake represents ﹤0.01% of the portfolio and ranks #3417 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ARCT as recently as Q3 2025.

Arax Advisory Partners first reported a position in ARCT in Q2 2024 and has held it in 5 quarters since. The position peaked at $10.8K in Q2 2024. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Arax Advisory Partners held 62 shares of Arcturus Therapeutics worth $479 as of Q1 2026.
  • Arcturus Therapeutics was a new Arax Advisory Partners position in Q1 2026.
  • Arcturus Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3417 holding.
  • Arax Advisory Partners first reported a position in Arcturus Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Arcturus Therapeutics position peaked at $10.8K in Q2 2024.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.